Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsA phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.
AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.
Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older
1.
Top FDA Official Exits; SCOTUS Takes Up Obamacare Case; Texas Doc Suspended
2.
Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.
3.
The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.
4.
The origin of BPH and prostate cancer in different prostate zones and the impact on the incidence of prostate cancer
5.
FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.
1.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
2.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
3.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
4.
Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success
5.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge